Artelo Secures Japanese Patent Allowance for ART27.13 Formulation
ARTL is trading near its 52-week low of $0.69 (2.5% above the low) on light trading volume (0.2× avg).
Summary
Artelo received a Notice of Allowance from the Japanese Patent Office for the intended commercial formulation of ART27.13, its dual cannabinoid agonist in two Phase 2 trials. This follows the USPTO allowance announced August 17 and extends protection to three major markets—US, Europe, and Japan—through 2041. The company also highlighted AstraZeneca's prior Phase 1 safety data in Japan showing comparable exposure and adverse events between Japanese and Caucasian participants. For a micro-cap trading near its 52-week low, this strengthens the global IP position of its lead asset and supports long-term commercial potential. Initial results from the DREAM glaucoma study are expected in Q4 2026.
At the time of this announcement, ARTL was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.69 to $31.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.